Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response
In Vivo · 2025
DOI: 10.21873/invivo.14161 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift In Vivo, 2025. Verfasst von Shogen Boku und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Cachexia, Neoplasms, Oligopeptides. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan.
- Department of Thoracic Oncology, Kansai Medical University, Hirakata, Japan.
- Department of Nursing, Kansai Medical University Hospital, Hirakata, Japan.
- Department of Nutrition, Kansai Medical University Hospital, Hirakata, Japan.
- Central Research Center, Institute of Biomedical Science, Kansai Medical University, Hirakata, Japan.
- Department of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, Hirakata, Japan.
Zitieren
APA
Boku, S., Yasuda, T., Ikoma, T., Matsumori, E., Yoshiuchi, S., Matsuo, Y., Higasa, K., & Kurata, T. (2025). Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response. In Vivo. https://doi.org/10.21873/invivo.14161
Vancouver
Boku S, Yasuda T, Ikoma T, Matsumori E, Yoshiuchi S, Matsuo Y, et al. Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response. In Vivo. 2025. doi:10.21873/invivo.14161
BibTeX
@article{Boku2025,
author = {Boku, Shogen and Yasuda, Tomoyo and Ikoma, Tatsuki and Matsumori, Eri and Yoshiuchi, Sawako and Matsuo, Yoshiyuki and Higasa, Koichiro and Kurata, Takayasu},
title = {Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.14161}
}
EUVIMED